Clarivate Plc (NYSE: CLVT) has completed the previously announced sale of its Life Sciences & Healthcare business to an affiliate of Altaris, LLC. The transaction, valued at $600 million, was finalized on October 6, 2026.
Under the terms of the Stock and Asset Purchase Agreement dated July 3, 2026, the Buyer paid $500 million in cash at closing. This amount is subject to customary adjustments for cash, indebtedness, working capital, and transaction expenses. Additionally, the Buyer issued an unsecured senior note with an aggregate principal amount of $75 million to Clarivate.
Clarivate also agreed to receive a deferred consideration of $25 million. This payment is due to the company upon the later of (x) 20 business days after Clarivate completes the transition services for the Buyer, (y) 20 business days after the final payment for those services is received, or (z) January 31, 2028.
In connection with the closing, Henry Levy, the company’s President of Life Sciences & Healthcare, terminated his employment with a subsidiary of Clarivate. Clarivate entered into a separation agreement with Mr. Levy providing for the payments and benefits outlined in his previously disclosed retention agreement.
Following the divestiture, Clarivate’s portfolio is now focused on two segments: Academia & Government and Intellectual Property. The company intends to use the transaction proceeds to reduce debt and strengthen its balance sheet.
Clarivate plans to file unaudited pro forma financial information reflecting the transaction by October 13, 2026. The company will report its third quarter 2026 financial results on November 3, 2026, and intends to update its full year 2026 guidance to reflect the divestiture.
